Laura Fletcher: Revealing OligoTune to the world launched in partnership with Cancer Research Horizons

Laura Fletcher, Head of Business Development at Deep Science Ventures, shared a post by Deep Science Ventures on LinkedIn:

“Super excited to start the day revealing OligoTune to the world, the 4th company we’ve launched from our strong partnership with Cancer Research Horizons.

OligoTune’s mission will be to remodel the tumour microenvironment via tackling multiple targets and cell types driving therapy resistance.

With huge thanks particularly to Hamish Ryder and Beatrice Lana for their vision and support. And of course to our awesome founder Loïc Roux for true commitment and tenacity – building a company like this is no mean feat! I cannot wait to see what the next chapter brings.”

Quoting Deep Science Ventures’ post:

“New company alert – today we announce the formation of OligoTune, built in partnership with Cancer Research Horizons and founded by Loïc Roux, to develop immunotherapies focused on solid tumours.

OligoTune focuses on reprogramming the immunosuppressive environment these tumours protect themselves with into one which instead promotes innate resistance against the tumours themselves. Link to the press release in comments!

Huge thanks to the massive group of people that came to enable this invention!”

Source: Laura Fletcher/LinkedIn and Deep Science Ventures/LinkedIn